암 생물학적 제제 시장 : 치료제, 세포 치료제, 암 백신별 - 세계 예측(2025-2030년)

The Cancer Biologics Market was valued at USD 96.71 billion in 2023, expected to reach USD 102.05 billion in 2024, and is projected to grow at a CAGR of 6.30%, to USD 148.35 billion by 2030.

Cancer biologics represent a rapidly evolving segment within the pharmaceutical industry, focused on using biological substances or systems to target cancer cells more precisely than traditional chemotherapies. These biologics include monoclonal antibodies, growth factor inhibitors, gene therapy, and personalized vaccines. Their necessity stems from the need for targeted therapeutics that minimize collateral damage to healthy cells, enhancing patient outcomes and reducing adverse effects. The application of cancer biologics spans from treatment to diagnostics and prognostics, with end-use scope including hospitals, clinics, and specialized cancer treatment centers.

The market for cancer biologics is being driven by increasing cancer prevalence, advancements in biotechnology, and a surge in R&D investments. Key growth factors include expanded healthcare access in emerging economies, regulatory support for biological drugs, and increasing patient awareness. One potential opportunity lies in the development of biosimilars, offering cost-effective alternatives to branded biologics. To seize this opportunity, companies should invest in robust clinical trials and navigate the biosimilar approval pathways effectively. Additionally, leveraging AI and machine learning for biomarker discovery can expedite personalized medicine approaches, offering significant growth prospects.

However, several challenges confront the market, including high development costs, stringent regulatory requirements, and the complexity of manufacturing biological products. Intellectual property and market competition also pose substantial hurdles, potentially leading to high pricing strategies that limit accessibility. For sustained growth, innovators should focus on improving manufacturing efficiencies and expanding collaborative research partnerships.

Promising areas of innovation include the exploration of novel therapeutic targets using CRISPR technology for gene editing and investigating the microbiome's role in cancer therapy. Understanding the competitive landscape and the nature of the market, which is characterized by rapid advancements and high competition, can position companies to effectively strategize and innovate. By addressing the challenges and leveraging emerging technological advancements, businesses can capitalize on the burgeoning opportunities presented by cancer biologics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biologics Market

The Cancer Biologics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of initiatives focused on early cancer detection and personalized treatment options
  • Technological advancements in biologic drug manufacturing leading to cost efficiency and higher production rates
  • Increasing collaborations between academic institutions and biopharmaceutical companies for cancer drug innovation
  • Expansion of healthcare infrastructure and access to biologics in emerging markets contributing to market growth
• Market Restraints
  • Complex supply chain and cold storage logistics create challenges in distribution and increase costs
  • Reimbursement and insurance coverage restrictions limit patient access to expensive biologics treatments
• Market Opportunities
  • Advancement in immunotherapy techniques enhancing treatment effectiveness and market penetration
  • Integrating artificial intelligence and machine learning in cancer biologics for predictive analytics
  • Expansion of cancer biologics in emerging markets due to increased diagnostic capabilities
• Market Challenges
  • Navigating complex regulatory approval processes for cancer biologics causing delays in market entry
  • Challenges in obtaining robust clinical trial data for proving the efficacy and safety of cancer biologics

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biologics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biologics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biologics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biologics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biologics Market

A detailed market share analysis in the Cancer Biologics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biologics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biologics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biologics Market

A strategic analysis of the Cancer Biologics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Incyte Corporation, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Seattle Genetics, and Takeda Pharmaceutical.

Market Segmentation & Coverage

This research report categorizes the Cancer Biologics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapies, market is studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Monoclonal Antibodies. The Conjugated Monoclonal Antibodies is further studied across Chemolabelled Antibodies and Radiolabelled Antibodies.
• Based on Cell Therapies, market is studied across Dendritic Cell Therapy, Natural Killer Cell Therapy, and T-Cell Therapy.
• Based on Cancer Vaccines, market is studied across Preventive Cancer Vaccines and Therapeutic Cancer Vaccines.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of initiatives focused on early cancer detection and personalized treatment options
    • 5.1.1.2. Technological advancements in biologic drug manufacturing leading to cost efficiency and higher production rates
    • 5.1.1.3. Increasing collaborations between academic institutions and biopharmaceutical companies for cancer drug innovation
    • 5.1.1.4. Expansion of healthcare infrastructure and access to biologics in emerging markets contributing to market growth
  • 5.1.2. Restraints
    • 5.1.2.1. Complex supply chain and cold storage logistics create challenges in distribution and increase costs
    • 5.1.2.2. Reimbursement and insurance coverage restrictions limit patient access to expensive biologics treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancement in immunotherapy techniques enhancing treatment effectiveness and market penetration
    • 5.1.3.2. Integrating artificial intelligence and machine learning in cancer biologics for predictive analytics
    • 5.1.3.3. Expansion of cancer biologics in emerging markets due to increased diagnostic capabilities
  • 5.1.4. Challenges
    • 5.1.4.1. Navigating complex regulatory approval processes for cancer biologics causing delays in market entry
    • 5.1.4.2. Challenges in obtaining robust clinical trial data for proving the efficacy and safety of cancer biologics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Biologics Market, by Therapies

• 6.1. Introduction
• 6.2. Bispecific Monoclonal Antibodies
• 6.3. Conjugated Monoclonal Antibodies
  • 6.3.1. Chemolabelled Antibodies
  • 6.3.2. Radiolabelled Antibodies
• 6.4. Monoclonal Antibodies

7. Cancer Biologics Market, by Cell Therapies

• 7.1. Introduction
• 7.2. Dendritic Cell Therapy
• 7.3. Natural Killer Cell Therapy
• 7.4. T-Cell Therapy

8. Cancer Biologics Market, by Cancer Vaccines

• 8.1. Introduction
• 8.2. Preventive Cancer Vaccines
• 8.3. Therapeutic Cancer Vaccines

9. Americas Cancer Biologics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Biologics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biologics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie
• 2. Amgen
• 3. AstraZeneca
• 4. Bayer
• 5. Biogen
• 6. Bristol-Myers Squibb
• 7. Celgene
• 8. Eli Lilly and Company
• 9. Gilead Sciences
• 10. GlaxoSmithKline
• 11. Incyte Corporation
• 12. Johnson & Johnson
• 13. Merck & Co.
• 14. Novartis
• 15. Pfizer
• 16. Regeneron Pharmaceuticals
• 17. Roche
• 18. Sanofi
• 19. Seattle Genetics
• 20. Takeda Pharmaceutical